Background: Dysferlin mutations cause progressive muscular dystrophies with strong inflammation, yet its function in immune cells is unclear.
Results: Dysferlin forms a protein complex with focal adhesion proteins, and its loss in monocytes results in deregulated adhesion.
Conclusion: Dysferlin is involved in regulating cellular interactions in human monocytes.
Significance: Dysferlin dysfunction in monocytes may contribute to pathology in dysferlinopathy.
Keywords: Cell Adhesion, Integrin, Monocytes, Muscular Dystrophy, Skeletal Muscle
Abstract
Dysferlin is mutated in a group of muscular dystrophies commonly referred to as dysferlinopathies. It is highly expressed in skeletal muscle, where it is important for sarcolemmal maintenance. Recent studies show that dysferlin is also expressed in monocytes. Moreover, muscle of dysferlinopathy patients is characterized by massive immune cell infiltrates, and dysferlin-negative monocytes were shown to be more aggressive and phagocytose more particles. This suggests that dysferlin deregulation in monocytes might contribute to disease progression, but the molecular mechanism is unclear. Here we show that dysferlin expression is increased with differentiation in human monocytes and the THP1 monocyte cell model. Freshly isolated monocytes of dysferlinopathy patients show deregulated expression of fibronectin and fibronectin-binding integrins, which is recapitulated by transient knockdown of dysferlin in THP1 cells. Dysferlin forms a protein complex with these integrins at the cell membrane, and its depletion impairs cell adhesion. Moreover, patient macrophages show altered adhesion and motility. These findings suggest that dysferlin is involved in regulating cellular interactions and provide new insight into dysferlin function in inflammatory cells.
Introduction
Mutations in the dysferlin gene (DYSF, MIM*603009) cause the progressive late onset muscular dystrophies limb girdle muscular dystrophy (LGMD) 2B (MIM#253601) (1), Miyoshi myopathy (MIM#254130) (2), and distal anterior compartment myopathy (MIM#606768) (3), collectively referred to as dysferlinopathies. All of them are characterized by an adult onset of muscle weakness followed by progressive muscle wasting. The muscle tissue presents with strong inflammatory infiltrates (4), and for that reason, the disease is often misdiagnosed as the immune disorder polymyositis. Dysferlin is a C2 domain-containing transmembrane protein that is highly expressed in skeletal muscle (5) and activated satellite cells (6), and increases with differentiation. In addition, it is expressed in monocytes (7, 8).
Recent studies suggest that the immune response in dysferlin-deficient tissue is compromised (9, 10). In muscle, dysferlin deficiency causes reduced cytokine (9, 10) and chemokine (11) secretion and a subsequent local misbalance in recruitment and persistence of immune cells (9). In dysferlin mouse models, neutrophils and macrophages appear later at the site of damage when compared with controls in degeneration/regeneration experiments (9). However, after their late appearance, these cells reside longer in the muscle tissue, suggesting a prolonged inflammatory response of these cells (9). Roche et al. (12) showed the existence of a strong immune component in dysferlin deficiency that contributes to its slower recovery from injury.
As dysferlin is strongly expressed in monocytes (7, 8), it was suggested that modified monocyte behavior might contribute to the dysferlin phenotype. Indeed, a recent study indicates that dysferlin-deficient macrophages have a higher phagocytosis index and are thus more aggressive than wild-type cells (13). However, the mechanism behind this observation is unclear.
We previously characterized the dysferlin protein complex in muscle and observed that dysferlin is found in complex with focal adhesion components in skeletal muscle cells (14). Focal adhesions are cellular attachment sites where the internal cytoskeleton is connected to the extracellular matrix via integrins (15). Integrins are heterodimeric transmembrane receptors that consist of an α- and a β-subunit and are central to focal adhesions (15). According to the traditional view, integrins link the extracellular matrix to the intracellular cytoskeleton (15, 16). However, recent studies also indicated a role for integrins in cell-cell contacts (16). Because of the uncharacterized role of dysferlin near focal adhesions and the deregulated monocyte response in dysferlinopathy patients, we investigated a potential function for dysferlin in monocyte cell adhesion. We observed a striking increase in macrophage motility in dysferlinopathy patients, in line with an altered adhesion propensity.
EXPERIMENTAL PROCEDURES
Cell Isolation and Culture
THP1 cells were grown at 37 °C and 5% CO2 in RPMI medium supplemented with 1% l-glutamine and 10% FCS (all Invitrogen). Peripheral blood mononuclear cells were isolated by a Ficoll gradient. CD3-positive T-cells, CD14-positive monocytes, and CDx-positive B-cells were subsequently isolated with antibody-coated magnetic beads (Invitrogen) according to the manufacturer's protocol. Cells were counted and resuspended in RPMI medium for further experiments. Monocytes were in vitro differentiated according to protocol (17), using established cytokine cocktails. Differentiation was monitored by FACS analysis of reported surface markers (CD11b or integrin αM (ITGAM)).4
Antibodies and Reagents
THP1 cells were differentiated by the addition of phorbol 12-myristate 13-acetate (sigma) at 20 nm to the culture medium. Cells were differentiated for 3–5 days for further experiments. The following matrixes were used in this study: fibronectin, rat collagen, poly-l-lysine. Matrix compounds were dissolved 1:30 in PBS, incubated on plastic 6-well plates at 37 °C for 2 h, and washed with PBS. Adhesion was monitored by light microscopy (bright field). The following antibodies were used in this study: MaDYSF (1;300 for Western blot and immunofluorescence, Hamlet, Novocastra), RaAHNAK (KIS, gift of Dr. J. Baudier), MaITGB3 (1;10,000, R&D), MaITGB1 (1;10,000, gift of W. J. Pannekoek), GaPARVB (1;1,000, Santa Cruz Biotechnology), MaVINC (1;5,000 Sigma), and MaACTN3 (1;5,000 Sigma).
Western Blot Detection
Cells were counted, dissolved in sample buffer, and boiled for 10 min. Resulting protein homogenates were separated on SDS-page gels and transferred onto nitrocellulose (for AHNAK) or PVDF membranes. Protein loading was standardized to cell count and monitored with Ponceau S staining of the blot directly after transfer. After antibody detection, blots were analyzed with an Odyssey scanner (LI-COR). Protein bands were quantified with ImageJ and Odyssey analysis software.
RNA Isolation and cDNA Synthesis
RNA was extracted with a RNA extraction kit (Macherey-Nagel) according to the manufacturer's protocol. Subsequent cDNA synthesis was performed with a kit and random hexamer primers (Fermentas) according to the manufacturer's instructions. 1 μg of RNA was used as input for cDNA reactions.
Quantitative RT-PCR
All primers were designed with the web tool Primer3, with mispriming against human database. Quantitative PCR reactions were performed with SYBR Green, in a 15-μl reaction volume with 3 ng of cDNA input. All primers had comparable efficiencies between 95 and 105%. All measurements were performed in triplicate. Statistical analysis was performed according to the method of Pfaffl (18). GAPDH was used as a reference gene.
DNA Plasmids and Transfection
The following shRNA plasmids out of the Sigma Mission shRNA library were used in this study: nontarget SHC002 and dysferlin TRCN0000000967. The dysferlin shRNA was validated by co-expression with dysferlin expression vector. 10 × 6 THP1 cells were washed in PBS and dissolved in Nucleofector buffer V. 0.5 μg of DNA plasmid was added. Transfection was achieved by electroporation with an Amaxa Nucleofector device. Transfected cells were resuspended in culture medium.
Immunostaining
Differentiated THP1 cells were fixed in formalin solution for 10 min followed by permeabilization in 0.3% Triton (Sigma) for 5 min. Cells were washed, blocked in 1% BSA (Sigma) for 10 min, and incubated with primary antibody for 2 h at room temperature. Cells were subsequently washed three times and incubated with secondary antibody for 1 h at room temperature. Cells were washed in PBS and mounted onto slides with Aqua-Poly/Mount supplemented with DAPI. For the visualization of the very transient focal adhesions, we used CSK (CyoSKeleton) buffer. THP1 cells were differentiated at coverslips for >3 days using phorbol 12-myristate 13-acetate. Cells were fixed with fresh CSK buffer (0.3% Triton, 10 mm Pipes, pH 7.0, 50 mm KCl, 2 mm CaCl2, 2 mm MgCl2, 300 mm sucrose, 4% paraformaldehyde) for 15 min. This treatment washed out all of the soluble cell components but fixed the cytoskeletal parts including the focal adhesions. The coverslips were subsequently washed two times in PBS and blocked with 1% BSA in PBS for >10 min. Next the coverslips were stained with the antibodies as mentioned above. For the endocytosis assays, cells were incubated for 1 h on ice with ITGB3 antibody at 1;10,000. Unbound antibody was washed off with PBS, and fresh medium was added. Cells were cultured at 37 °C for 1 h. Endocytosis was stopped by putting the cells on ice. Surface antibody was washed off with 0.2 mm glycine (pH 2.5). Next cells were prepared as otherwise. As a control, cells were analyzed directly after antibody incubation, confirming that all surface-bound antibody could be washed off by the glycine treatment (not shown). To inhibit the integrins, differentiated THP1 cells were incubated in 1 μg/ml GRGDS (Sigma) or a control peptide (SDGRG, Sigma). For the ITGB3 stimulation, cells were incubated with ITGB3 antibody at 37 °C.
Immunoprecipitation
To obtain total cell lysates, differentiated THP1 cells were lysed by scraping in Triton buffer (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 0.2% Triton X-100, 1× protease inhibitor mixture (Roche Applied Science)) after a PBS wash. Cultured cells were prepared freshly by washing in PBS and lysed by scraping on ice in lysis buffer. All homogenates were spun down at maximum speed, 4 °C, 20 min. To generate subcellular fractions, differentiated THP1 cells were trypsinized and washed with PBS. The pellet was lysed in sucrose buffer (320 mm sucrose, 5 mm HEPES (pH 7.4), 5 mm EDTA, 2× protease inhibitor mixture) with a Dounce homogenizer. Lysates were spun down subsequently at 1,000 × g (P1, containing insoluble debris), 10,000 × g (P2, containing mitochondria and peroxisomes), and 100,000 × g (P3, enriched for cell membrane, endoplasmic reticulum and vesicles (microsomes)). Pellet fractions were dissolved in Triton buffer for further immunoprecipitations. Protein A-Sepharose CL-4B (GE Healthcare) was washed three times in lysis buffer and used to preclear the homogenates for 1 h, at 4 °C, with tumbling. Sepharose was removed, and antibody was added (50 μg of HCAb) for overnight incubation at 4 °C, with tumbling. Thereafter washed Sepharose was added and incubated for 2 h, 4 °C, with tumbling. Homogenates were spun down at 500 × g, and supernatant was stored as unbound fraction. The Sepharose was washed five times, three times short and two times long (>20 min of tumbling at 4 °C). Finally, all fluid was removed, and protein was eluted by boiling in sample buffer.
Macrophage Culture and Video and Immunocytochemistry
Blood samples from five patients and five healthy controls were extracted using Vacutainer CPT tubes (BD Biosciences, Basel, Switzerland). CD14+ monocytic cells were separated using the negative selection purple EasySep cell selection system (STEMCELL Technologies, Grenoble, France). Monocytes were differentiated into macrophages during 6 days in culture medium based on RPMI 1640 supplemented with 10% FBS, 1% glutamine, 1% sodium pyruvate, penicillin-streptomycin, and fungizone and amino acids in poly-d-lysine precoated Lumox plates (Sarstedt, Nümbrecht, Germany). Macrophages were filmed in a laser scanning confocal inverted microscope Leica TCS SP5-AOBS (Leica Microsystems, Wetzlar, Germany) during 18 h at 37 °C and 5% CO2. The videos were analyzed using Leica LAS AF software. In the end, we were able to gather data on 29 macrophages from five dysferlinopathy patients and 17 macrophages from five controls. The distance covered by each studied cell was measured every 30 min. Comparison between control macrophages and dysferlin-negative macrophages was performed using a Student's t test. To determine the purity of macrophage cultures, cells were fixed in cold methanol for 10 min at 4 °C and blocked with Tris-buffered saline supplemented with 1% BSA, 1% normal human serum, 0.5% donkey serum, and 0.01% Triton X-100. A primary monoclonal antibody to CD68 (Dako, Glostrup, Denmark) was incubated for 2 h at room temperature and labeled with donkey anti-mouse Alexa Fluor 488 (Invitrogen).
RESULTS
Dysferlin Expression Is Enhanced in Differentiating Monocytes
Previous studies show that dysferlin is expressed in monocytes and macrophages (7, 8, 13). To confirm this observation, we purified B cells, T cells, and monocytes from freshly isolated peripheral blood mononuclear cells from healthy donors and investigated dysferlin protein levels on Western blot. Dysferlin is expressed only in monocytes, confirming prior observations, whereas its interaction partner AHNAK (19) is expressed in all three cell types (Fig. 1A). We next differentiated freshly isolated monocytes in vitro to a pro-inflammatory (M1) or contra-inflammatory (M2) phenotype and again tested for dysferlin and AHNAK expression on Western blot (Fig. 1B). Both proteins are increased with differentiation in both M1 and M2 macrophages. Interestingly, the monocyte-like leukemic THP1 cell model shows a similar increase in dysferlin and AHNAK upon differentiation (Fig. 1B). Finally, we measured RNA expression levels of dysferlin and AHNAK in THP1 cells (Fig. 1, C and D). Again, we found a strong up-regulation of dysferlin. AHNAK, however, is up-regulated to a much smaller extent, suggesting that the increase in AHNAK protein levels is achieved through a different mechanism than that for dysferlin. We conclude that dysferlin and AHNAK are increased with monocyte differentiation.
FIGURE 1.
Dysferlin is expressed in monocytes and THP1 cells and increases with differentiation. A, fresh peripheral blood mononuclear cells (PBMCs) were isolated from a healthy donor. CD3-positive T-cells, CD14-positive monocytes, and CD19-positive B-cells (right panel) were subsequently isolated from this cell population. Cells were analyzed freshly or cultured for 24 h in culture medium, in the presence or absence of T-cell activation aCD3 antibody, to investigate the effect on protein expression. Cells were dissolved in sample buffer and analyzed on Western blot for AHNAK and dysferlin levels. Arrows denote the protein bands. For the dysferlin-negative B-cells, two different donors are shown. B, monocytes were differentiated in vitro to M1 and M2 macrophages and analyzed on Western blot for AHNAK and dysferlin. Less protein was loaded when compared with the previous panel. Additionally, the THP1 cell model was differentiated to a macrophage-like phenotype and similarly analyzed. Arrows denote the protein bands. C, quantitative RT-PCR was performed on differentiating THP1 cells to confirm the increase in expression on RNA levels. Uncorrected Ct values confirm the increased expression of dysferlin in differentiating THP1 cells. Two different primer sets were used to measure dysferlin mRNA. Both the small and the long isoform of AHNAK were assayed (41). D, Ct values were standardized to GAPDH. Relative expression levels are shown. Error bars reflect relative S.D. of technical variation.
Dysferlin Expression Is Insensitive to Cell-Matrix Contact Formation
In skeletal muscle, dysferlin functions as a calcium-sensitive membrane repair protein (20). In a THP1 cell scratch-wounding assay, dysferlin displayed a calcium-dependent recruitment to the lesion site (data not shown), indicating that in monocytes, dysferlin also participates in calcium-sensitive membrane repair. However, it is not likely that monocytes suffer from frequent membrane damage as do myofibers, challenging the biological relevance of the membrane repair function of dysferlin in monocytes. We therefore explored potential additional functions of dysferlin. We and others previously reported that dysferlin forms a complex with focal adhesion components, which are important in cell-cell and cell-matrix contacts (14, 21). Monocytes require interactions with the extracellular matrix and surrounding cells to exert their function. THP1 cells are nonadherent prior to differentiation and become adherent upon differentiation. We therefore investigated whether dysferlin and AHNAK expression levels are sensitive to cell adherence. We first measured the mRNA expression levels of various matrix and adherence proteins in differentiating THP1 cells (Fig. 2A). This showed dysferlin expression to be concomitantly up-regulated with fibronectin and integrins α5, αV, β1, and β3. Interestingly, the integrins α5β1 and αVβ3 have fibronectin binding capacity. We could not detect up-regulated expression of other matrix proteins such as laminin (Fig. 2A). This suggests that the THP1 cells adhere to fibronectin. The same genes were up-regulated in in vitro differentiated M1 and M2 macrophages (Fig. 2B). We proceeded to test THP1 cell adhesion on protein matrixes. We coated wells with PBS (mock), poly-l-lysine, collagen, or fibronectin. Poly-l-lysine is positively charged and attracts all cells to the surface without adherence, whereas fibronectin and collagen are matrix proteins. Fig. 2C shows that on plastic surfaces, dysferlin and AHNAK proteins are only increased upon the induction of differentiation. A similar effect is seen for poly-l-lysine. Fibronectin, however, increases AHNAK protein levels, yet not dysferlin, even in the absence of differentiation. Indeed, the cells adhere onto a fibronectin matrix without achieving the spread-out differentiated phenotype (not shown). Dysferlin again only increases upon differentiation. Finally, the collagen matrix has no strong effect on either protein unless the cells were differentiated. We conclude that dysferlin expression does not respond to cell-matrix adhesion, contrary to AHNAK, which is sensitive to fibronectin adherence.
FIGURE 2.
Dysferlin expression is insensitive to cell adhesion. A and B, quantitative RT-PCR shows selective increased expression of fibronectin (FN) and fibronectin-binding integrins upon differentiation of THP1 cells (A) and in vitro differentiated macrophages (B). Values were standardized to GAPDH. In B, monocyte expression levels were set to 1. Error bars in A and B reflect relative S.D. of technical variation. C, THP1 cells were seeded on different protein matrixes, and dysferlin protein expression was quantified by Western blot. Dysferlin increases only upon differentiation (induced by phorbol 12-myristate 13-acetate (PMA) addition). AHNAK increases in response to fibronectin adhesion. Arrows denote the AHNAK and dysferlin protein bands.
Differentiation-induced Dysferlin Expression Is Enhanced in Response to Cell-Cell Contact Formation
We next investigated dysferlin and AHNAK expression in response to cell-cell contacts. We differentiated THP1 cells at increasing cell densities, predicting that this would result in an increased frequency of cell-cell contact formation. Surprisingly, the differentiation-induced dysferlin mRNA expression levels are further increased with increasing cell density, suggesting a positive response to cell-cell contact formation (Fig. 3). The integrins ITGA5, ITGAV, ITGB1, and ITGB3 show the opposite pattern, with expression levels dropping with increasing cell density (Fig. 3A). Nevertheless, apart from their function in cell-matrix contacts, integrins are also important for cell-cell contacts (16, 22). The dysferlin interaction partner AHNAK shows an increase in expression similar to dysferlin but followed by a sudden drop at the highest cell density tested. It is not clear why this happens, but given its function in cell interactions (23, 24), its increase may be a response to the loss of the cell in integrin expression. To verify that dysferlin protein is involved in cell-cell contacts, we performed immunofluorescent staining experiments on differentiated THP1 cells. Dysferlin strongly accumulates at cell-cell contacts (Fig. 3B), together with ITGB3. Intriguingly, the proteins AHNAK and ITGB1 are also strongly present at cell-cell contacts (not shown), although their RNA expression levels are insensitive to cell density. This indicates that dysferlin plays a role at cell-cell contacts.
FIGURE 3.
Dysferlin expression is sensitive to cell-cell contact formation. A, THP1 cells were differentiated at different cell densities, and after 3 days, RNA expression was determined by quantitative RT-PCR. Values were standardized to GAPDH. Error bars reflect relative S.D. of technical variation. FN, fibronectin. B, differentiated THP1 cells were stained for dysferlin (green) and ITGb3 (red). Nuclei are stained in blue (DAPI). Dysferlin and ITGB3 accumulate in between the two nuclei.
Loss of Dysferlin Protein Results in Deregulation of Integrin Expression
To obtain more evidence that dysferlin is important for cell adhesion, we transfected THP1 cells with an shRNA plasmid to knock down dysferlin (Fig. 4, A and B). We confirmed a substantial reduction of dysferlin protein levels by Western blotting (Fig. 4B). We measured RNA (Fig. 4A) and protein (Fig. 4B) expression levels during differentiation and observed that ITGB1 and ITGB3 and fibronectin are much more strongly up-regulated in the dysferlin-depleted cells, whereas other markers such as CD11b (ITGAM) appear unaffected. This shows that integrin mRNA expression is affected by the absence of dysferlin, which is suggestive of a change in cell adhesion properties. We next measured RNA expression levels in a confirmed patient with LGMD2B and a matched control and observed a strikingly similar deregulation of fibronectin and the fibronectin-binding integrins in the patient cells (Fig. 4C). Intriguingly, however, in the patient, we did not detect an increase in ITGB3, nor did we detect a decrease in ITGAM. Based on these markers, the cells of the patients resemble more the M2 macrophages as shown in Fig. 2B. Finally, we performed cell counts at 4 days after differentiation of mock-transfected and dysferlin-depleted THP1 cells. In wild-type cells, most of the cells adhere to the surface after 4 days of differentiation. Transfection with a nontarget shRNA plasmid results in a slight decrease in adherent cells, probably due to the transfection procedure. However, depletion of dysferlin results in a strong reduction in cell adhesion (Fig. 4E). We stained shRNA-transfected THP1 cells for surface ITGB3. Again, this showed a clear loss of adherent cells, but no difference in surface ITGB3 could be detected between dysferlin-depleted and control cells in the adherent cells. This suggests that the localization of integrins is unaffected by dysferlin depletion, but leaves open the possibility of altered dynamics. We conclude that dysferlin is involved in integrin-mediated THP1 monocyte cell adhesion.
FIGURE 4.
Dysferlin depletion results in deregulated integrin expression and decreased cell adhesion. A, transient shRNA-mediated knockdown of dysferlin further up-regulates upon induction of differentiation the mRNA expression levels of fibronectin (FN) and fibronectin-binding integrins. B, a concomitant Western blot shows only a minor increase in protein level. Mono, monocytes; NT, nontarget shRNA. C, freshly isolated monocytes from an LGMD2B patient and a healthy matched control were analyzed for mRNA expression levels. D and E, THP1 cells were transfected with a dysferlin-targeting shRNA plasmid, a nontarget shRNA plasmid, or mock-transfected and differentiated for 4 days. After 4 days, adherent cells were counted (D) and stained for surface ITGB3 (E). In the absence of dysferlin, cell adhesion is strongly reduced. There is no difference in the level of surface ITGB3 in the adherent cells. Error bars in A, C, and D reflect relative S.D. of technical variation.
Dysferlin Can Form a Complex with Focal Adhesion Components
In skeletal muscle cells, dysferlin forms a complex with vinculin and associated focal adhesion proteins (14). To test whether dysferlin is physically associated with adhesion complexes, we performed immunoprecipitation experiments on protein homogenates from differentiated THP1 cells. In addition to total homogenates, we also analyzed cellular subfractions enriched for organelles or microsomes (Fig. 5). We used two independent dysferlin-specific heavy chain antibody fragments (VHH) and one nonspecific VHH, as described previously (14, 25), and analyzed co-immunoprecipitation by Western blot. Dysferlin is found in all fractions. Moreover, ITGB3, vinculin, paxillin, and β-parvin co-immunoprecipitate with dysferlin from the microsomal fraction, suggesting that as in muscle cells, dysferlin forms a complex with a subset of focal adhesions in THP1 cells. ITGB1 does not co-immunoprecipitate with dysferlin. It should be noted that in the total cell extract, no detectable amount of ITGB3 co-immunoprecipitates with dysferlin, suggesting that the interaction takes place at the focal adhesion only. Also we observe that the amount of protein that is immunoprecipitated with dysferlin is modest, suggesting that the interactions either are transient or concern only a subset of the proteins. To further substantiate the evidence for dysferlin near focal adhesions, we performed co-immunofluorescence experiments with an antibody against the focal adhesion protein vinculin (Fig. 5C). Focal adhesions have a rapid turnover. Therefore we fixed the cells with the stringent CSK buffer. This allowed for detection of vinculin in focal adhesions. Dysferlin partially co-localizes with vinculin at these focal adhesions. This modest co-localization might suggest that the interaction is transient in nature. We conclude that dysferlin can form a protein complex with focal adhesion components in monocytes.
FIGURE 5.
ITGb3 and focal adhesion components co-immunoprecipitate with dysferlin. Differentiated THP1 cells were lysed in a sucrose buffer, fractionated, and subjected to an immunoprecipitation (IP) protocol with HCAb against dysferlin (F4 and H7) or nonspecific control HCAb (3A). Bound (B) and unbound (NB) fractions were analyzed on Western blot for dysferlin and focal complex proteins. A, P1 (1,000 g) contains the insoluble fraction, P2 (10,000 g) is enriched for heavy organelles such as mitochondria and nuclei, and P3 (100,000 × g) is enriched for microsomes and contains cell membrane and vesicles. B, immunoprecipitation fractions were analyzed for dysferlin and ITGB3 levels (upper blot), ITGB1, ACTN3, PAX, VINC, and the described interaction partner PARVB (lower blot). Contrary to ITGB1, ITGB3 co-immunoprecipitates from the P3 fraction containing microsomes (H7-bound). This same immunoprecipitation sample also contains ACTN3, PAX, and PARVB, suggesting that complete focal complexes co-immunoprecipitate with dysferlin. C, co-immunostaining of the focal adhesion protein vinculin with dysferlin. Two representative cells are shown. The cell in the lower panels is completely removed by the CSK buffer, and only the focal adhesions remain. The cell in the upper panels has some membranous and cytoskeletal parts remaining. The arrows point to the enhanced part.
Dysferlin Endocytosis in Response to Integrin Stimulation
A recent study by Sharma et al. (26) suggested a role for dysferlin in the trafficking of the adhesion molecule PECAM (platelet endothelial cell adhesion molecule) in endothelium. We therefore studied the trafficking of dysferlin and ITGB3 in THP1 cells with co-immunofluorescence staining. We observed that in resting differentiated THP1 cells, dysferlin and ITGB1 or ITGB3 do not strongly co-localize (Fig. 6A). This confirms the immunoprecipitation data on whole cell lysates and supports the hypothesis that both proteins are together only at the cell membrane or on endocytic vesicles. We therefore decided to stimulate integrin endocytosis by incubating differentiated THP1 cells with a small peptide (GRGDS) containing the matrix-binding site for integrin (RGD). This peptide competes for the matrix-binding site. Upon binding the peptide, the integrin is endocytosed (Fig. 6B), and it is replaced by exocytosis of integrin molecules from an intracellular storage. We used a low concentration that removed the focal adhesions in the cell protrusions (stained by vinculin in Fig. 6B), but prevented the cells from rounding up and detaching, and we stained the cells for dysferlin and ITGB3. Both proteins show a rapid response to GRGDS and accumulate in a perinuclear compartment (Fig. 6A). This recruitment is specific for dysferlin and ITGB3, as subsequent co-staining for dysferlin and AHNAK showed the latter to shift toward the cell periphery (Fig. 6C).
FIGURE 6.
Dysferlin and integrin β3 (ITGB3) are endocytosed in response to the integrin-inhibiting peptide RGD. A, differentiated THP1 cells were incubated 30 min with an integrin-binding peptide (RGD). Cells were stained for dysferlin and ITGB3. Prior to RGD stimulus, there is no apparent co-localization between dysferlin and ITGB3. Both proteins show a dotted intracellular localization reminiscent of endosomes. Upon stimulation, both proteins accumulate in an intracellular compartment. B, images and a schematic model of integrin trafficking and RGD stimulus. RGD prevents the integrins from binding to the extracellular matrix and thereby stimulates endocytosis. C, as in A, but now the cells were stained for dysferlin and AHNAK. Only dysferlin is recruited intracellularly. In the control situation, cells were incubated with a control peptide containing the inverse amino acid sequence (SDGRG), which does not bind integrins. D, differentiated THP1 cells were incubated with a monoclonal MaITGB3 antibody and stained for dysferlin and ITGB3. Both proteins are recruited to a perinuclear compartment. E, Integrin β3 is endocytosed upon RGD stimulus. Differentiated THP1 cells were incubated with MaITGB3 at 4 °C for 1 h. Cells were washed and incubated 30 min at 37 °C with RGD. Surface-bound antibody was removed with glycine, and cells were stained for internalized ITGB3 and dysferlin. Both proteins accumulate at the perinuclear storage compartment, indicating that ITGB3 is endocytosed.
Many integrin heterodimers have the potential to bind to an RGD peptide motif (27), and all these heterodimers might be inhibited by the GRGDS treatment. However, our data thus far suggested that mainly ITGB3 is functionally linked to dysferlin. To test this, we incubated cells in the presence of a monoclonal antibody specific for the extracellular part of ITGB3. This resulted in a similar recruitment of both ITGB3 and dysferlin (Fig. 6D), suggesting that the GRGDS-induced trafficking of dysferlin is largely caused by ITGB3 inhibition.
To prove that the integrins undergo endocytosis upon GRGDS stimulation, we incubated differentiated THP1 cells with the integrin β3 antibody on ice prior to GRGDS stimulation. Subsequent stimulation with GRGDS at 37 °C resulted in intracellular ITGB3 antibody, strongly indicating that the integrins are indeed endocytosed in response to the GRGDS treatment (Fig. 6E). As there is no antibody available that binds to the extracellular domain of dysferlin, it is technically not feasible to confirm this in a similar experimental setup for dysferlin. We conclude that dysferlin is co-endocytosed with ITGB3.
Dysferlinopathy Macrophages Move Faster
Our data thus far suggest that dysferlin locates to monocyte cell adhesion sites and that it is involved in cell interactions. We therefore hypothesized that cell adhesion might be disturbed in monocytes of dysferlinopathy patients. To test this, we isolated and cultured human primary macrophages from five molecularly confirmed LGMD2B patients and five healthy matched control donors. All isolated cells stained positive for the marker CD68, confirming the purity of our cultures (Fig. 7A). We performed live cell microscopy to monitor the cells and record their movements. Strikingly, we observed that dysferlinopathy macrophages are more motile than their healthy counterparts (Fig. 7, B and C). Specifically, dysferlinopathy macrophages covered more distance and had a 60% increase in average velocity (13.85 μm/h when compared with 8.71 μm/h for controls, with p = 0.00009). These data are consistent with the reduced adhesion in dysferlin-depleted THP1 cells and with a role for dysferlin in regulation of cellular interactions.
FIGURE 7.
LGMD2B monocytes move faster than control cells. A, macrophage culture stained with DAPI and the macrophage marker CD68. B, graphic representation of average velocity and S.D. in μm/h of healthy macrophages (Controls) and dysferlin-null macrophages (Patients) (p = 0.00009). C, pictures of the 18-h tracking by control macrophages (Control) and dysferlin-null macrophages (Patient).
DISCUSSION
We report that dysferlin expression is up-regulated in differentiating monocytes and the THP1 monocyte cell model. Dysferlin localizes to the cell membrane of monocytes and is rapidly endocytosed with ITGB3 upon inhibition of this integrin. Dysferlin forms a complex with ITGB3 and focal adhesion components at the cell periphery. Moreover, our data indicate that in the absence of dysferlin, the regulation of fibronectin-binding integrins is disturbed. Dysferlin depletion further enhances the increase in ITGB3 expression. This results in attenuated differentiation and adhesion of these cells, which mimics the loss of adhesion observed in dysferlin-depleted human umbilical vein endothelial cells (26). In dysferlinopathy macrophages, this reveals itself as increased cell motility. Interestingly, monocytes expressing ITGB3 show increased motility (28) when compared with cells without ITGB3.
During the recruitment of mononuclear cells to inflamed tissue, these cells first need to adhere to the endothelial cell and start the process of rolling. They subsequently transmigrate through the endothelial cell layer, and finally, they migrate through the tissue to participate in phagocytosis of apoptotic cells. The attachment of circulating monocytes to endothelial cells is in part mediated by integrins that bind to endothelial vascular cell adhesion protein (VCAM) molecules and thereby induce tight interaction between the two cell types (29). Such cell-cell interactions generally increase the levels of integrin expression (15) by positive feedback, thereby gradually increasing adherence to facilitate subsequent transmigration.
Our data suggest that dysferlin-depleted THP1 cells adhere less efficiently, but nevertheless increase expression of integrins. Integrins can be activated by outside-in and by inside-out signaling. Outside-in signaling refers to the process where integrins are activated through adhesion and trigger signaling cascades in the cells. Inside-out signaling denotes relocalization of integrins, for instance during motility, to provide direction (15). Via outside-in signaling, integrins can affect ERK, JNK, and PKB and thereby affect gene expression (15). Moreover, cells have numerous feedback mechanisms that link expression of different adhesion proteins. For example, monocyte cell adhesion results in increased levels of fibronectin (30). Moreover, such feedback loops can be negative as integrin αVβ6 can compensate for the loss of ITGB1 (31, 32). Therefore the increased integrin mRNA expression in the absence of dysferlin may be explained as a compensatory mechanism. In muscle, similar negative feedback loops have been described for dysferlin. Dysferlin-deficient muscle cells produce increased amounts of IL1β (10) and thrombospondin (11), suggesting that dysferlin inhibits expression of these proteins.
When comparing the mRNA expression levels in dysferlinopathy patient monocytes with dysferlin-depleted THP1 cells, the deregulated expression of ITGB1 is consistent, contrary to ITGB3. However, cross-talk between integrins is common and has been reported between ITGB1 and ITGB3 in monocytes. ITGB1 (α5β1) is regulated by ITGB3 (αVβ3) in phagocytosis experiments (33). Cross-talk between αVβ3 and α4β1 regulates monocyte migration on VCAM1 (34). Such cross-talk might explain the apparent discrepancy of the mRNA expression data.
We observed that dysferlin and ITGB3 trafficking is co-regulated. This is consistent with the role of dysferlin in the transport of the adhesion protein PECAM in endothelium (26). Moreover, the fact that focal adhesion components are identified in the dysferlin protein complex in both monocytes and myoblasts suggests parallels in dysferlin function between these cells. Indeed, the process of phagocytosis has been implicated to be analogous to endocytosis, and both processes require coordinated restructuring of cell membrane and the cortical actin-based cytoskeleton. Interestingly, ITGB1 and ITGB3 are involved in phagocytosis of both apoptotic cells and fibronectin-coated beads by monocytes (35). Moreover, fibronectin is used by monocytes for opsonization and enables ITGB1-dependent phagocytosis (36). This suggests that the disturbed LGMD2B monocyte phagocytosis behavior might be explained by a specific subset of fibronectin-binding integrins. An intriguing model would be that dysferlin-deficient monocytes show increased integrin endocytosis. Given the parallels between endocytosis and phagocytosis, this might translate into the increased phagocytic behavior that was shown in LGMD2B monocytes (13). It is tempting to hypothesize that the integrin deregulation also results in a modified phagocytic response. This would open the way for a potential immunomodulatory treatment of dysferlinopathy, and such immunotherapies aimed at integrins are currently being investigated for other diseases (37, 38).
Although recent studies provided evidence that the cause of the pathology in dysferlin-deficient mouse models is intrinsic to the skeletal muscle tissue (39, 40), the role of the immune component was unclear. It was suggested that the inflammation aggravates the disease (39). A defect in monocytes due to dysferlin deficiency could result in a misappropriate immune response, and thus aggravate the muscle disease. Chiu et al. (9) reported that in dysferlin-deficient mouse muscle tissue, monocytes arrive later after notexin-induced myofiber damage. This was explained by a deregulated communication from the myofibers to recruit the monocytes (9). Our data, however, provide an additional explanation. In the absence of dysferlin, the monocytes and macrophages show strongly reduced adhesion and increased motility, which might influence the infiltration.
In summary, we have identified a potential involvement of dysferlin in cellular adhesion and thereby a potential mechanism for the deregulation of dysferlin-deficient immune cells.
Acknowledgments
We thank Dr. J. Baudier for the KIS AHNAK antibody and Dr. W. J. Pannekoek for the ITGB1 and paxilin antibodies and for help with the focal adhesion stainings.
This work was supported by the Jain Foundation.
- ITGAM
- integrin αM
- HCAb
- heavy chain antibody.
REFERENCES
- 1. Bashir R., Britton S., Strachan T., Keers S., Vafiadaki E., Lako M., Richard I., Marchand S., Bourg N., Argov Z., Sadeh M., Mahjneh I., Marconi G., Passos-Bueno M. R., Moreira Ede S., Zatz M., Beckmann J. S., Bushby K. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat. Genet. 20, 37–42 [DOI] [PubMed] [Google Scholar]
- 2. Matsuda C., Aoki M., Hayashi Y. K., Ho M. F., Arahata K., Brown R. H., Jr. (1999) Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy. Neurology 53, 1119–1122 [DOI] [PubMed] [Google Scholar]
- 3. Illa I., Serrano-Munuera C., Gallardo E., Lasa A., Rojas-García R., Palmer J., Gallano P., Baiget M., Matsuda C., Brown R. H. (2001) Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann. Neurol. 49, 130–134 [PubMed] [Google Scholar]
- 4. Gallardo E., Rojas-García R., de Luna N., Pou A., Brown R. H., Jr., Illa I. (2001) Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57, 2136–2138 [DOI] [PubMed] [Google Scholar]
- 5. Anderson L. V., Davison K., Moss J. A., Young C., Cullen M. J., Walsh J., Johnson M. A., Bashir R., Britton S., Keers S., Argov Z., Mahjneh I., Fougerousse F., Beckmann J. S., Bushby K. M. (1999) Dysferlin is a plasma membrane protein and is expressed early in human development. Hum. Mol. Genet. 8, 855–861 [DOI] [PubMed] [Google Scholar]
- 6. De Luna N., Gallardo E., Illa I. (2004) In vivo and in vitro dysferlin expression in human muscle satellite cells. J. Neuropathol. Exp. Neurol. 63, 1104–1113 [DOI] [PubMed] [Google Scholar]
- 7. De Luna N., Freixas A., Gallano P., Caselles L., Rojas-García R., Paradas C., Nogales G., Dominguez-Perles R., Gonzalez-Quereda L., Vílchez J. J., Márquez C., Bautista J., Guerrero A., Salazar J. A., Pou A., Illa I., Gallardo E. (2007) Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul. Disord. 17, 69–76 [DOI] [PubMed] [Google Scholar]
- 8. Gallardo E., de Luna N., Diaz-Manera J., Rojas-García R., Gonzalez-Quereda L., Flix B., de Morrée A., van der Maarel S., Illa I. (2011) Comparison of dysferlin expression in human skeletal muscle with that in monocytes for the diagnosis of dysferlin myopathy. PLoS One 6, e29061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Chiu Y. H., Hornsey M. A., Klinge L., Jørgensen L. H., Laval S. H., Charlton R., Barresi R., Straub V., Lochmüller H., Bushby K. (2009) Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum. Mol. Genet. 18, 1976–1989 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Rawat R., Cohen T. V., Ampong B., Francia D., Henriques-Pons A., Hoffman E. P., Nagaraju K. (2010) Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am. J. Pathol. 176, 2891–2900 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. De Luna N., Gallardo E., Sonnet C., Chazaud B., Dominguez-Perles R., Suarez-Calvet X., Gherardi R. K., Illa I. (2010) Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy. J. Neuropathol. Exp. Neurol. 69, 643–653 [DOI] [PubMed] [Google Scholar]
- 12. Roche J. A., Lovering R. M., Roche R., Ru L. W., Reed P. W., Bloch R. J. (2010) Extensive mononuclear infiltration and myogenesis characterize recovery of dysferlin-null skeletal muscle from contraction-induced injuries. Am. J. Physiol. Cell Physiol 298, C298–312 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Nagaraju K., Rawat R., Veszelovszky E., Thapliyal R., Kesari A., Sparks S., Raben N., Plotz P., Hoffman E. P. (2008) Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am. J. Pathol. 172, 774–785 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. de Morrée A., Hensbergen P. J., van Haagen H. H., Dragan I., Deelder A. M., 't Hoen P. A., Frants R. R., van der Maarel S. M. (2010) Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 5, e13854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Hynes R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673–687 [DOI] [PubMed] [Google Scholar]
- 16. Chattopadhyay N., Wang Z., Ashman L. K., Brady-Kalnay S. M., Kreidberg J. A. (2003) α3β1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion. J. Cell Biol. 163, 1351–1362 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Xu W., Roos A., Schlagwein N., Woltman A. M., Daha M. R., van Kooten C. (2006) IL-10-producing macrophages preferentially clear early apoptotic cells. Blood 107, 4930–4937 [DOI] [PubMed] [Google Scholar]
- 18. Pfaffl M. W. (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29, e45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Huang Y., Laval S. H., van Remoortere A., Baudier J., Benaud C., Anderson L. V., Straub V., Deelder A., Frants R. R., den Dunnen J. T., Bushby K., van der Maarel S. M. (2007) AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J. 21, 732–742 [DOI] [PubMed] [Google Scholar]
- 20. Bansal D., Miyake K., Vogel S. S., Groh S., Chen C. C., Williamson R., McNeil P. L., Campbell K. P. (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423, 168–172 [DOI] [PubMed] [Google Scholar]
- 21. Matsuda C., Kameyama K., Tagawa K., Ogawa M., Suzuki A., Yamaji S., Okamoto H., Nishino I., Hayashi Y. K. (2005) Dysferlin interacts with affixin (β-parvin) at the sarcolemma. J. Neuropathol. Exp. Neurol. 64, 334–340 [DOI] [PubMed] [Google Scholar]
- 22. Davis D. M. (2009) Mechanisms and functions for the duration of intercellular contacts made by lymphocytes. Nat. Rev. Immunol. 9, 543–555 [DOI] [PubMed] [Google Scholar]
- 23. Benaud C., Gentil B. J., Assard N., Court M., Garin J., Delphin C., Baudier J. (2004) AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture. J. Cell Biol. 164, 133–144 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Salim C., Boxberg Y. V., Alterio J., Féréol S., Nothias F. (2009) The giant protein AHNAK involved in morphogenesis and laminin substrate adhesion of myelinating Schwann cells. Glia 57, 535–549 [DOI] [PubMed] [Google Scholar]
- 25. Huang Y., Verheesen P., Roussis A., Frankhuizen W., Ginjaar I., Haldane F., Laval S., Anderson L. V., Verrips T., Frants R. R., de Haard H., Bushby K., den Dunnen J., van der Maarel S. M. (2005) Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur. J. Hum. Genet. 13, 721–730 [DOI] [PubMed] [Google Scholar]
- 26. Sharma A., Yu C., Leung C., Trane A., Lau M., Utokaparch S., Shaheen F., Sheibani N., Bernatchez P. (2010) A new role for the muscle repair protein dysferlin in endothelial cell adhesion and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 30, 2196–2204 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Ruoslahti E. (1996) RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697–715 [DOI] [PubMed] [Google Scholar]
- 28. Weerasinghe D., McHugh K. P., Ross F. P., Brown E. J., Gisler R. H., Imhof B. A. (1998) A role for the αvβ3 integrin in the transmigration of monocytes. J. Cell Biol. 142, 595–607 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Imhof B. A., Aurrand-Lions M. (2004) Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 4, 432–444 [DOI] [PubMed] [Google Scholar]
- 30. Thomas-Ecker S., Lindecke A., Hatzmann W., Kaltschmidt C., Zänker K. S., Dittmar T. (2007) Alteration in the gene expression pattern of primary monocytes after adhesion to endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 104, 5539–5544 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Raghavan S., Bauer C., Mundschau G., Li Q., Fuchs E. (2000) Conditional ablation of β1 integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination. J. Cell Biol. 150, 1149–1160 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Raghavan S., Vaezi A., Fuchs E. (2003) A role for αβ1 integrins in focal adhesion function and polarized cytoskeletal dynamics. Dev. Cell 5, 415–427 [DOI] [PubMed] [Google Scholar]
- 33. Blystone S. D., Graham I. L., Lindberg F. P., Brown E. J. (1994) Integrin αvβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J. Cell Biol. 127, 1129–1137 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Imhof B. A., Weerasinghe D., Brown E. J., Lindberg F. P., Hammel P., Piali L., Dessing M., Gisler R. (1997) Cross talk between αvβ3 and α4β1 integrins regulates lymphocyte migration on vascular cell adhesion molecule 1. Eur. J. Immunol. 27, 3242–3252 [DOI] [PubMed] [Google Scholar]
- 35. Dupuy A. G., Caron E. (2008) Integrin-dependent phagocytosis: spreading from microadhesion to new concepts. J. Cell Sci. 121, 1773–1783 [DOI] [PubMed] [Google Scholar]
- 36. Vernon-Wilson E. F., Auradé F., Brown S. B. (2006) CD31 promotes β1 integrin-dependent engulfment of apoptotic Jurkat T lymphocytes opsonized for phagocytosis by fibronectin. J. Leukocyte Biol. 79, 1260–1267 [DOI] [PubMed] [Google Scholar]
- 37. Gottlieb A., Krueger J. G., Bright R., Ling M., Lebwohl M., Kang S., Feldman S., Spellman M., Wittkowski K., Ochs H. D., Jardieu P., Bauer R., White M., Dedrick R., Garovoy M. (2000) Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J. Am. Acad. Dermatol. 42, 428–435 [DOI] [PubMed] [Google Scholar]
- 38. Jackson D. Y. (2002) α4 integrin antagonists. Curr. Pharm. Des. 8, 1229–1253 [DOI] [PubMed] [Google Scholar]
- 39. Lostal W., Bartoli M., Bourg N., Roudaut C., Bentaïb A., Miyake K., Guerchet N., Fougerousse F., McNeil P., Richard I. (2010) Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum. Mol. Genet. 19, 1897–1907 [DOI] [PubMed] [Google Scholar]
- 40. Millay D. P., Maillet M., Roche J. A., Sargent M. A., McNally E. M., Bloch R. J., Molkentin J. D. (2009) Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am. J. Pathol. 175, 1817–1823 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. de Morrée A., Droog M., Grand Moursel L., Bisschop I. J., Impagliazzo A., Frants R. R., Klooster R., van der Maarel S. M. (2012) Self-regulated alternative splicing at the AHNAK locus. FASEB J. 26, 93–103 [DOI] [PubMed] [Google Scholar]







